Walvax subsidiary chosen for HPV vaccine program, secures loan and patent

Walvax Biotechnology Co., Ltd. announced that its subsidiary, Yuxi Zerun Biological Technology Co., Ltd., has been shortlisted for the 2025 National Immunization Program's centralized procurement project for bivalent human papillomavirus (HPV) vaccine at a unit price of RMB 27.5. This entry is expected to expand the company's HPV vaccine sales and market penetration. The bivalent HPV vaccine was launched in 2022 and received WHO PQ pre-qualification in August 2024.

In a related development, Walvax Biotechnology's board approved a RMB 670,000,000.00 acquisition loan from Yunnan Hongta Bank Co., Ltd. The loan, secured by a pledge of 166,483,967 shares of Yuxi Walvax Biotechnology Co., Ltd., facilitates the acquisition of an 11.3043% equity stake in Yuxi Walvax for RMB 1,639,123,500.00.

Additionally, Walvax Biotechnology announced the receipt of an invention patent for "a thermostatic shaker for vaccine shake flask culture," which is expected to enhance the company's intellectual property protection and core competitiveness.